靶向JAK-STAT信号通路治疗银屑病的研究进展  

Targeting the JAK-STAT signaling pathway in the treatment of psoriasis

作　　者：何谐 栗玉珍[1] He Xie;Li Yuzhen(Department of Dermatology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院皮肤科,150081

出　　处：《中华皮肤科杂志》2023年第3期273-278,共6页Chinese Journal of Dermatology

基　　金：国家自然科学基金(81773320)。

摘　　要：银屑病的发生与Janus激酶(JAK)-信号转导及转录激活因子(STAT)通路密切相关, 白细胞介素(IL)-23、IL-22、γ干扰素等多种细胞因子均可通过该通路传递信号, 从而促进银屑病中角质形成细胞增殖及异常分化、炎症细胞浸润等病理过程, 提示靶向该通路是治疗银屑病的新策略。近年来, 小分子JAK抑制剂治疗银屑病显示出较好的疗效和安全性, 而靶向STAT的药物正在开发阶段, 为银屑病的治疗提供了更多选择。该文综述靶向JAK-STAT信号通路治疗银屑病的研究进展。The Janus kinase(JAK)-signal transducer and activator of transcription(STAT)signaling pathway is closely related to the occurrence of psoriasis.Various cytokines,including interleukin(IL)-23,IL-22,interferon(IFN)-γ,etc.,can promote some key pathologic processes(such as the proliferation and abnormal differentiation of keratinocytes,and infiltration of inflammatory cells)via the JAK-STAT pathway in psoriasis,which suggests that targeting JAK-STAT pathway is a new strategy for the treatment of psoriasis.In recent years,small-molecule JAK inhibitors have shown good efficacy and safety in the treatment of psoriasis,and drugs targeting STAT pathway have been under development,which provide more treatment options for psoriasis.This review summarizes progress in drugs targeting JAK-STAT signaling pathway in the treatment of psoriasis.

关 键 词：银屑病 Janus激酶类 STAT转录因子类 治疗 JAK-STAT信号通路 JAK抑制剂 STAT抑制剂 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]